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Efficient Conjugation of Oligosaccharides to Polymer Particles by 
Furan/Maleimide Diels-Alder Reaction: Application to the Capture 
of Carbohydrate-Binding Proteins 
Antoine Petrelli, ab Eric Samain, ab Stéphanie Pradeau, ab Sami Halila, ab Sébastien Fortab* 
Abstract: Glycan-protein interactions play a crucial role in 
physiological and pathological events. Hence, improving the isolation 
of carbohydrate-binding proteins (i.e. lectins and anti-glycan 
antibodies) from complex media can not only lead to a better 
understanding of their function, but also provides solutions for public 
health issues, such as water contamination or the need for universal 
blood plasma. Herein, we report a rapid and efficient method to 
produce carbohydrate-based affinity adsorbents combining enzymatic 
synthesis and metal-free click chemistry. Simple as well as complex 
glycans (maltose, blood group antigens A, B and H) were readily 
modified by the addition of a furyl group at their reducing end without 
the need for protecting groups and then efficiently conjugated to 
maleimide-activated Sepharose particles via a Diels-Alder reaction. 
These neoglycoconjugates showed high efficiency for the purification 
of lectins (Concanavalin A and Ulex europaeus agglutinin) as well as 
for the capture of anti-A and anti-B blood group antibodies, opening 
new prospects for glycoproteomics and for the development of 
universal blood plasma. 
Introduction 
All cells and eukaryotic cells in particular, are coated by a 
glycocalyx constituted of glycoconjugates, i.e. glycolipids and 
glycoproteins, of extraordinary diversity. The glycan moieties are 
located on the external face of the cell membrane, and act as a 
recognition signal, thereby fulfilling unique biological functions. 
Specific interactions between these carbohydrates and lectins or 
anti-glycan antibodies are involved in many biological events in 
healthy and in diseased states of living organisms. In particular, 
carbohydrate-directed cell adhesion appears to be important in 
cellular communication, in the immune response and in infection 
by bacteria and viruses.[1]  
Synthetic neoglycoconjugates in which a glycan is covalently 
linked to a protein, a lipid or a solid matrix have proven to be 
efficient tools to study structure-function relationships of complex 
carbohydrates. They also have many practical applications for the 
diagnosis and treatment of various diseases. For example, 
immobilized carbohydrates constitute versatile affinity adsorbents 
for the purification of enzymes,[2] lectins[3] and antibodies.[4] The 
depletion of anti-glycan antibodies in sera is beneficial for 
therapeutic developments and analytical studies of autoimmune 
diseases, such as the Guillain-Barré syndrome and Crohn’s 
disease.[5] Carbohydrate-based immunoadsorbents have been 
shown to be efficient and safe in organ transplantation across the 
ABO blood group barrier.[6] They also hold promise to improve 
universal blood plasma supply.[7] Indeed, plasma which contains 
clotting factors, immunoglobulins and albumin is used in every 
day medicine, emergencies and surgical medicine to treat clotting 
disorders, burn, and shock victims. However, universal AB 
plasma, which does not contain any antibodies against either A or 
B antigens, is usually in short supply because of the scarcity of 
this blood group.  
The production of neoglycoconjugates for the above-mentioned 
applications is hindered by the lack of an efficient method to 
synthesize complex oligosaccharides and to conjugate them 
without extensive protecting-group manipulation. Enzymatic 
syntheses, and particularly those employing microbial cell 
factories, have considerably improved access to complex 
oligosaccharides. High density culture of metabolically 
engineered E. coli cells can produce a wide range of mammalian 
molecules on a multigram scale, including gangliosides,[8] 
globosides[9] and Lewis antigens.[10] Current procedures used to 
immobilize native oligosaccharides on solid matrices can for their 
part  be classified into two categories. The first involves the 
nucleophilic attack of any hydroxyl group present on the 
carbohydrate onto an electrophile, typically an epoxide,[11] a 
cyanate[12] or a vinyl sulfone[13] ester. The lack of regioselectivity 
of these reactions does not allow a controlled orientation of the 
ligand, thus restricting their use to commonly available and cheap 
mono- and disaccharides. The second strategy consists of the 
specific modification of the reducing end of the glycan by 
reductive amination[14] or by the formation of hydrazone[15] or 
oxime[16] linkages. Although these procedures are efficient on an 
analytical scale, large-scale applications have the major 
drawback of requiring the use of harmful chemicals. Furthermore, 
they also often lead to the loss of the cyclic structure of the 
modified sugar unit, which may result in a lower affinity for the 
target protein.[17] 
The advent of click chemistry in 2001 sparked a renewed interest 
in the development of effective methods for the mild and site-
specific conjugation of biomolecules including carbohydrates. The 
copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC), the 
most prominent example of click-reactions, has found myriad 
applications in chemical biology.[18] 
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Scheme 1. General synthesis route for the preparation of carbohydrate-modified Sepharose particles and chemical structures of furyl-modified maltose (1) and 
furyl-modified blood group antigens H (2), A (3) and B (4)
The Diels-Alder cycloaddition, is also an attractive reaction for the 
conjugation of biomolecules, since besides being a 
chemoselective, reversible and catalyst-free reaction, it is fast and 
efficient in aqueous media.[19] Diels-Alder reactions have been 
successfully applied to the preparation of oligosaccharide-based 
antibacterial vaccines[20] and biosensors.[21] Usual dienes 
employed for these syntheses are cyclopentadiene, heptadienoic 
acid or tetrazine derivatives. Curiously, the furan group has been 
scarcely used for the conjugation of biomolecules except for a few 
examples such as for the synthesis of peptide–oligonucleotide 
conjugates[22] or DNA-porphyrin conjugates.[23] However, the 
furan-maleimide cycloaddition currently meets a great success in 
material science as an effective crosslinking method especially for 
the preparation of hydrogels.[24]  
Herein, we describe an efficient protocol for the preparation of 
new carbohydrate-based affinity adsorbents using furan-
maleimide cycloaddition. Blood group antigens H,[25] A and B[26] 
were produced in E. coli and readily turned into N-furfuryl-
glycosylamides before being conjugated to maleimide-activated 
Sepharose particles via a Diels-Alder reaction. The resulting 
neoglycoconjugates were then assessed as affinity adsorbents 
for the purification of lectins and for the capture of antibodies. The 
synthesis route for these new carbohydrate-based affinity 
adsorbents is depicted in Scheme 1. 
Results and Discussion 
Sepharose 4B, which is a well-proven agarose gel filtration base 
matrix for affinity chromatography, was selected as the solid 
support. The commercially available succinimidyl ester-activated 
form was reacted with N-(2-aminoethyl)maleimide[27] to introduce 
a dienophile group which is amenable to a Diels-Alder reaction. 
The unreacted activated esters were then hydrolyzed in mild basic 
conditions to avoid the degradation of the maleimide moiety. The 
conversion yield was at least 85%, as determined by the 
conductimetric titration of unreacted and total theoretical reactive 
sites. Infrared (IR) spectroscopy analysis further confirmed the 
introduction of the maleimide groups by the absence of the 
characteristic succinimidyl ester peaks at 1738 and 1782 cm-1 and 
the presence of the maleimide carbonyl peak at 1710 cm-1 (Figure 
1). 
 
Figure 1. IR spectrum of modified Sepharose in the carbonyl region: A) 
Sepharose, B) Maltose-modified Sepharose, C) Maleimide-activated 
Sepharose, D) NHS-activated Sepharose. 
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The modification and conjugation of carbohydrates were then 
investigated on maltose as a model before moving to more 
complex oligosaccharides. Furyl-maltose conjugate 1 was 
prepared in 84% yield by reacting unprotected maltose in neat 
furylamine to afford a transient glycosylamine that was made non-
hydrolyzable by selective N-acylation in methanol. This 
carbohydrate-modification method which was originally 
developed by Lokhoff et al.[28] with aliphatic amines and 
disaccharides for the synthesis of glycolipid analogues then 
showed a great versatility when applied to various amines and 
sugars. Among the different examples reported in the literature 
about the use of this reaction, one could notice the direct 
immobilization of reductive oligosaccharides onto polymer beads 
for the preparation of chromatography adsorbents[29] and the 
synthesis of glycosylated carriers for gene transfection.[30] 
Glycosylamides derived from unsaturated amines such as 
allylamine or propargylamine also have been shown to be 
interesting intermediates in the synthesis of glycoconjugates by 
thiol-ene and CuAAC reactions.[31] Our group has efficiently used 
this approach for the preparation of drug nanocarriers[32] and 
nanoorganized thin films[33] by self-assembly of oligosaccharide-
based block copolymers.  
The furyl-maleimide Diels-Alder reaction was carried out in water 
under gentle stirring of the Sepharose particles with a fivefold 
excess of 1. The time-course of the reaction was monitored by IR 
spectroscopy (Figure 1). During the conjugation, the alkene 
moiety of the maleimide was consumed in the cycloaddition, thus 
shifting the maleimide carbonyl signal from 1710 cm-1 to 1696 cm-
1. Although an excess of furyl-maltose 1 was required to drive the 
reaction to completion, it was recovered unaltered after rinsing the 
particles. IR analysis suggested that all maleimide groups 
underwent complete reaction.  
For confirmation, we determined the maltose content on the solid 
matrix by enzymatic digestion. To do so, the particles were 
incubated with an excess of recombinant amyloglucosidase G2[34] 
and the amount of glucose released in the supernatant was 
assessed using the BCA reducing sugar assay. We thus 
confirmed that the Diels-Alder ligation in water proceeded with an 
extremely satisfactory yield of at least 85%. Moreover, the 
efficiency of enzymatic hydrolysis with amyloglucosidase also 
confirmed the availability of the immobilized carbohydrate moiety 
for protein binding.  
 
Figure 2. Enzyme-linked lectin assay absorbance at 450 nm of the supernatant 
after o-phenylenediamine/H2O2 treatment: of 0.1mL of 1) Maleimide-activated 
Sepharose with 10 µg ConA-HRP 2) Maltose-modified Sepharose with 10 µg 
peanut-HRP (PNA), 3-6) Maltose-modified Sepharose with 0 µg (3), 5 µg (4), 
10 µg (5) and 20 µg (6) of ConA-HRP 
To further characterize the maltose-modified Sepharose 
adsorbent, we examined its specificity for Concanavalin A (ConA) 
lectin in an enzyme-linked lectin assay (Figure 2).[35] As one would 
expect, the binding of horseradish peroxydase-ConA conjugate 
(ConA-HRP) onto the maltose-functionalized adsorbent showed 
a dose-dependent response. To confirm that the adsorption of 
ConA was not resulting from a non-specific interaction with the 
support, a control experiment was performed with maleimide-
activated Sepharose particles. No colorimetric response was 
observed when incubating ConA with the non-glycosylated 
Sepharose particles thus attesting of the absence of non-specific 
binding. The specificity of maltose-modified Sepharose toward 
ConA was also further confirmed by the absence of color 
development upon incubation with HRP-conjugated Arachis 
hypogaea (peanut) lectin (PNA-HRP) a galactose-binding protein. 
These findings prompted us to evaluate the maltose-modified 
Sepharose particles as a matrix for lectin affinity chromatography. 
Gel capacity was calculated by saturating maltose-modified 
Sepharose particles (1 mL, 50% vol. slurry) with ConA (5 mg) and 
after washing with PBS, eluting the lectin with a 0.2 M solution of 
free maltose. The protein content in the eluted fraction was 
determined using the Bradford assay. The gel showed a binding 
capacity of 2 mg of ConA lectin per milliliter resin. The same 
column was then incubated with a mixture composed of 1.5 mg of 
ConA and 3 mg of BSA for 1 h (Figure 3). After washing with PBS 
buffer until no protein was detectable in the eluate, the lectin was 
desorbed with a 0.2 M solution of maltose and quantified using a 
Bradford assay. According to the titration, 84% of ConA was 
recovered. The composition of the different fractions was 
analyzed by SDS-PAGE electrophoresis (Figure 4). As expected, 
the wash fractions contained BSA and little or no ConA was 
detected, confirming its strong and specific interaction on the 
matrix. Moreover, the electrophoretic bands in lanes 5 and 6 show 
only ConA (Figure 4) without any contaminant thus attesting to 
successful separation.  
 
Figure 3. Purification of a 1:2 ConA:BSA mixture (w/w) on a maltose-modified 
Sepharose. 
3
4
5
6
0.5
1
1.5
2
2.5
3
3.5
0 5 10 15 20 25 30
A
b
s
o
rb
a
n
c
e
 (
5
9
5
n
m
)
Volume (mL)
Maltose 0.2 M
 c 
1 2 3
4
5
6
0
0.2
0.4
0.6
0.8
1
1.2
1.4
A
b
s
o
rb
a
n
c
e
 (
4
5
0
 n
m
) 
    
 
 
 
 
 
 
Figure 4. SDS-PAGE of ConA/BSA Purification, lane 0) size marker, lane 1) 
BSA, lane 2) ConA standard, lanes 3,4,5,6) fractions 3-6. 
These results obtained with maltose clearly demonstrate that the 
Diels-Alder reaction is a straightforward and efficient method for 
conjugating carbohydrates to Sepharose particles. Furthermore, 
the Sepharose-supported carbohydrate was readily accessible for 
protein binding with an enzyme and a lectin.  
Encouraged by these results, we adapted this process to the 
preparation of novel immunosorbents for serum purification by 
immobilization of the A, B and H glycan blood group antigens on 
Sepharose particles. The glycans were produced by bacterial 
synthesis in metabolically engineered E. coli cells[25, 26] and 
chemically modified with a furfuryl group as described above. 
Again, the anomeric functionalization occurred in high yields 
despite the more complex structure of the glycans. The furyl 
glycoconjugates 2, 3 and 4 were isolated in 88%, 78% and 90% 
yield respectively after purification by flash chromatography on 
silica gel. A Diels-Alder reaction with furyl conjugates 2, 3 and 4 
and maleimide-activated Sepharose afforded neoglyconjugates 
which were evaluated for protein binding with Ulex europaeus 
agglutinin (UEA lectin), anti-A and anti-B antibodies for the H, A 
and B antigens, respectively. Anti-H monoclonal antibodies are 
not present in ABO blood groups, except for the rare Bombay 
phenotype[36] thus UEA lectin was used to probe the H-antigen 
matrix. UEA was labeled with the CF-488™ fluorescent staining 
kit according to the procedure indicated by the manufacturer and 
was used directly without any particular purification. As expected, 
UEA lectin did not show any affinity for the control maltose-
modified Sepharose particles, but it was efficiently adsorbed onto 
the H antigen-modified Sepharose and then specifically eluted by 
a 0.2 M solution of free H-antigen trisaccharide i.e 2’-fucosyl 
lactose (see Supporting Information).The affinity of the A and B 
blood group antigen-modified adsorbents was then assessed by 
fluorescence microcopy. Monoclonal anti-blood group A and B 
antibodies were obtained from Sigma-Aldrich as culture 
supernatants. Since the discrimination between mAbs is not 
possible by electrophoresis, they were labeled with two distinct 
fluorophores: CF-488™ (green) and CF-568™ (red) dyes for the 
anti-A and anti-B antibodies, respectively. The blood group 
adsorbents were individually incubated with the corresponding 
mAb, rinsed and observed under fluorescence microscopy. As 
shown in Figure 5B, the antigen A-modified Sepharose particles 
were coated with a strong green fluorescence after being in 
contact with anti-A mAb, but the control maltose-modified 
particles remained unlabeled under the same conditions.  
 
 
Figure 5.  Microscopy image (20x) of maltose-modified Sepharose particles 
incubated with anti-A mAb: under bright field (A), with FITC filter (A’), Antigen 
A-modified Sepharose particles incubated with anti-A mAb under bright field (B), 
with FITC filter (B’), mixture of antigen A and B-modified Sepharose particles 
incubated with anti-A and anti-B mAbs under bright field (C), and with FITC filter 
and DS-red filter (C’). 
These results once again confirm that the carbohydrate epitope 
on the solid matrix is available for protein binding and also that 
the interaction is highly specific, which is an important feature for 
potential medical applications. Anti-B antibodies were similarly 
specifically adsorbed onto the antigen B-modified Sepharose 
particles (see Supporting Information). Finally, Figure 5C shows 
a mixture of anti-A and anti-B labeled antibodies after 
simultaneous incubation with antigen A-modified particles and 
antigen B-modified particles. Despite the high structural analogy 
between A and B antigens, which differ only by an N-acetyl moiety 
on the terminal sugar, no cross-reactivity occurred and each 
antibody selectively recognized its corresponding antigen. 
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Conclusions 
In conclusion, we developed a rapid, high-yielding method for the 
anomeric functionalization of complex carbohydrates by 
introducing a furfuryl group and avoiding tedious protecting-group 
chemistry. The resulting glycoconjugates were immobilized very 
efficiently on a solid Sepharose matrix via a Diels-Alder 
cycloaddition in water and in the absence of any catalyst. This 
method therefore constitutes an interesting alternative to CuAAC 
click chemistry. Furthermore, any valuable, unreacted 
oligosaccharides can be recovered unaltered after ligation. The 
glycan-modified Sepharose particles were then assessed as 
affinity adsorbents for carbohydrate-binding proteins. Lectins 
were purified with high efficiency and great ease, opening new 
prospects for high-throughput protein screening. Additionally, 
anti-blood group A and B antibodies were specifically captured 
onto Sepharose particles conjugated with their respective 
antigens. Exciting applications of these immunosorbents include 
the preparation of antibody-free universal blood plasma. 
Expanding this approach to other glycan antigens may also offer 
new opportunities for the treatment of autoimmune diseases such 
as the Guillain-Barré syndrome. Finally, this robust and versatile 
bioconjugation approach should also benefit other fields of 
applications such as the development of nanocarriers for drug 
delivery or the stabilization of therapeutic proteins among others 
because of the growing interest of oligosaccharides in these areas. 
 
Experimental Section 
Materials: NHS-activated Sepharose 4B Fast flow GE Healthcare, 
furfurylamine, maleic anhydride, acetic anhydride; ethylene diamine, 
ethanolamine, di-tert-butyl dicarbonate, Mix-n-Stain™ CF™ 488A, Mix-n-
Stain™ CF™ 568 antibody labeling kit were purchased from Sigma-Aldrich 
and used as received. Native and HRP-conjugated lectins (Ulex 
europaeus UEA-I, Concanavalin A from Canavalia ensiformis and Arachis 
hypogaea agglutinin PNA) were purchased from Sigma-Aldrich. 
Amyloglucosylase AM-G2 from Aspergillus Niger was generously provided 
by Prof. Birte Svensson[34]. Monoclonal anti-blood group A and anti-blood 
group B antibodies produced in mouse were purchased from Sigma-
Aldrich as culture supernatant and the buffer was exchanged to PBS using 
Centricon™ 10kDa centrifugal filtration units prior to use. Maltose hydrate 
was purchased from Sigma-Aldrich and lyophilized prior to use. All 
solvents were purchased from Carlos Erba and were used without prior 
purification. N-tert-Butoxycarbonyl-ethylenediamine, N-(2-((tert-
Butoxycarbonyl)amino)ethyl)maleimide, and N-(2-Aminoethyl)maleimide 
hydrochloride were synthesized according to literature.[27] Protein were 
titrated with BioRad coomassie-blue assay by mixing the diluted dye with 
5 volumes of the protein solution, vortexing, incubating the sample 10min 
and reading the absorbance at 595nm. Protein sample were denatured by 
dissolving in TRIS HCl (0.1M), 20% Glycerol, 5% sodium dodecyl sulfate, 
5% dithiothreitol and boiled for 5 min. Electrophoresis was carried on SDS-
PAGE 12% at 35mA for one hour prior staining with coomassie blue.  
Equipments: Proton and Carbon nuclear magnetic resonance (HNMR) 
analyses were recorded at 25°C on a Bruker Advance DRX400 
spectrometer.[37] Chemical shifts (δ) are given in ppm. The solvent residual 
peak of D2O was used as internal standards and calibrated at 4.75 ppm. 
Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) 
measurements were performed on a Bruker Daltonics Autoflex apparatus 
using 2,5-dihydroxybenzoic acid (DHB) as a matrix. High resolution mass 
spectrometry was carried on a Waters Xevo™ G2-S QTOF (quadrupole 
hybrid with orthogonal acceleration time-of-flight) mass spectrometer 
apparatus. Fluorescence experiments were carried out on a Perkin Elmer 
LS-50B spectrometer with a pulsed high pressure xenon source using 
Hellma® Analytics suprasil quartz cuvettes. Fluorescence microscopy 
images were taken with a Zeiss Axio Vert.A1 epifluorescence microscope 
using either a FITC or DS-red filter. UV-visible measurements were carried 
out on a Varian® Carry 50 Bio spectrometer. 
Synthesis of furyl glycoconjugates 
General procedure for the synthesis of N-acetamido-N-furfuryl 
modified oligosaccharides: Lyophilized oligosaccharide was dissolved 
in the smallest volume of furfurylamine possible to get a homogeneous 
solution and the reaction mixture was stirred for 72h at 25°C. The solution 
was concentrated and co-evaporated with toluene. The crude 
glycosylamine was then dissolved in methanol (typically at 1g/10mL) and 
acetic anhydride (50% V/V) was slowly added at 0°C to the solution. The 
reaction mixture is then allowed to warm up to room temperature and 
stirred a further 16h. The solution was then concentrated and co-
evaporated with toluene. The residue was dissolved in 14% aqueous 
ammonia, stirred 1h at room temperature to hydrolyse potential O-acetyl 
groups. After concentration of the solution to half of its initial volume under 
vacuum, the aqueous phase was extracted 3 times with ethyl acetate to 
remove any free N-acetyl furfurylamine and freeze dried. Crude N-
acetamido-N-furfuryl-carbohydrates displayed satisfactory purity as 
judged by 1H NMR (see Supporting Information). However, a purification 
by flash chromatography on silica gel (CH3CN/H2O 9:1 to 8:2 v/v) was 
carried out for complete characterization prior to grafting onto the 
Sepharose particles.  
Maltosyl-N-acetamido-N-furfurylamine (1): Maltosyl-N-acetamido-N-
furfurylamine 1 was isolated in 84% yield (11.3 g) after purification.  The 
reaction was conducted with 10 g of maltose in 20 mL of furfurylamine. 
Acetylation was carried out in 100 mL of methanol in presence of 50 mL of 
acetic anhydride. 1H NMR (400 MHz, D2O) δ 7.49-7.43 (m, 1H, -O-CH=CH 
rotamers), 6.44-6.34 (m, 2H, -O-CH=CH- rotamers ), 5.51 (d, 0.4H, J = 9.0 
Hz, H1Glc-1 rotamers), 5.42 (m, 1H, H1Glc-II), 5.09 (d, 0.6H, J = 9.0 Hz, H1Glc-
1 rotamers), 4.69-4.53 (m, 2H, -CH2NAc), 3.89-3.39 (m, 12H, H2Glc I-II -H5Glc 
I-II), 2.29-2.24 (2s, 3H, NCOCH3 rotamers); 13C NMR (100 MHz, D2O) δ 
176.56, 175.35, 151.16, 150.59, 142.84, 142.16, 110.69, 108.55, 108.22, 
99.58, 86.65, 82.47, 77.24, 76.94, 76.66, 76.49, 76.15, 76.01, 72.85, 72.72, 
71.71, 71.67, 70.24, 69.71, 69.33, 60.73, 60.65, 60.48, 40.91, 37.47, 21.86, 
21.27; ESI-HRMS: m/z calcd for C19H29NO12  [M+Na]+ 486.1588, found 
486.1584. 
Fuc-α(1-2)-Gal-β(1-4)-Glc-β-N-acetamido-N-furfurylamine (Blood 
group H antigen) (2): Furyl-modified blood group H antigen 
oligosaccharide 2 was isolated in 88% yield (1.1 g) after purification. The 
reaction was conducted with 1 g of 2’-fucosyl lactose in 2 mL of 
furfurylamine. Acetylation was carried out in 10 mL of methanol in 
presence of 5 mL of acetic anhydride. 1H NMR (400 MHz, D2O) δ 7.49-
7.43 (m, 1H, -O-CH=CH rotamers), 6.44-6.34 (m, 2H, -O-CH=CH- 
rotamers), 5.49 (d, 0.4H, J = 9.0 Hz, H1Glc rotamers), 5.31 (m, 1H, H1Fuc), 
5.04 (d, 0.6H, J = 9.0 Hz, H1Glc rotamers), 4.69-4.52 (m, 3H, H1Gal, -
CH2NAc), 4.22 (m, 1H), 3.94-3.51 (m, 15H), 2.29-2.24 (2s, 3H, NCOCH3 
rotamers), 1.23 (d, 3H, J = 6.6 Hz, MeFuc); 13C NMR (100 MHz, D2O) δ 
176.66, 175.30, 151.13, 150.55, 142.86, 142.17, 110.69, 108.57, 108.23, 
100.33, 100.23, 99.36, 86.87, 82.60, 77.40, 77.32, 76.35, 76.23, 75.37, 
75.31, 75.26, 75.13, 74.94, 73.60, 71.68, 70.26, 69.63, 69.18, 68.22, 68.18, 
66.98, 66.95, 61.19, 60.14, 60.01, 40.95, 37.55, 21.85, 21.26, 15.34, 
    
 
 
 
 
 
15.28; ESI-HRMS: m/z calcd for C25H39NO16  [M+Na]+ 632.2167, found 
632.2157. 
GalNAc-α(1-3)-[Fuc-α(1-2)]-Gal-β(1-4)Glc-β-N-acetamido-N-
furfurylamine (Blood group A antigen) (3): Furyl-modified blood group 
A antigen oligosaccharide 3 was isolated in 78% yield (21 mg) after 
purification. The reaction was conducted with 23 mg of blood group A 
antigen oligosaccharide in 0.5 mL of furfurylamine. Acetylation was carried 
out in 1 mL of methanol in presence of 0.5 mL of acetic anhydride. 1H NMR 
(400 MHz, D2O) δ 7.49-7.43 (m, 1H, -O-CH=CH rotamers), 6.44-6.34 (m, 
2H, -O-CH=CH- rotamers), 5.49 (d, 0.4H, J = 9.0 Hz, H1Glc rotamers), 5.35 
(m, 1H, H1Fuc), 5.17 (d, 1H, J = 3.7 Hz, H1GalNAc), 5.02 (d, 0.6H, J = 9.0 Hz, 
H1Glc rotamers), 4.66-4.55 (m, 3H, H1Gal, -CH2NAc), 4.34-4.18 (m, 4H), 
3.99-3.50 (m, 18H), 2.29-2.24 (2s, 3H, NCOCH3 rotamers), 2.03 (s, 3H, 
NHCOCH3GalNAc) 1.25 (d, 3H, J = 6.6 Hz, MeFuc); 13C NMR (400 MHz, D2O) 
δ 176.69, 175.29, 174.84, 151.12, 150.55, 142.86, 142.18, 110.69, 108.56, 
108.23, 100.15, 100.06, 98.61, 98.55, 91.35, 86.91, 82.55, 77.46, 77.40, 
75.76, 75.49, 75.37, 75.24, 75.03, 72.34, 72.24, 71.70, 71.12, 70.30, 69.95, 
69.65, 68.50, 67.81, 67.68, 66.93, 63.11, 61.33, 61.26, 60.14, 60.00, 49.51, 
40.88, 37.54, 21.97, 21.83, 21.27, 15.19, 15.13; ESI-HRMS: m/z calcd for 
C33H52N2O21  [M+Na]+ 835.2960, found 835.2941. 
Gal-α(1-3)-[Fuc-α(1-2)]-Gal-β(1-4)Glc-β-N-acetamido-N-furfurylamine 
(Blood group B antigen) (4): Furyl-modified blood group B antigen 
oligosaccharide 4 was isolated in 90% yield (22 mg) after purification. The 
reaction was conducted with 21 mg of blood group B antigen in 0.5 mL of 
furfurylamine. Acetylation was carried out in 1 mL of methanol in presence 
of 0.5 mL of acetic anhydride. 1H NMR (400 MHz, D2O) δ 7.49-7.43 (m, 
1H, -O-CH=CH rotamers), 6.44-6.34 (m, 2H, -O-CH=CH- rotamers), 5.49 
(d, 0.4H, J = 9.0 Hz, H1Glc rotamers), 5.34-5.24 (m, 2H, H1Fuc, H1Gal’), 5.03 
(d, 0.6H, J = 9.0 Hz, H1Glc rotamers), 4.69-4.54 (m, 3H, H1Gal, -CH2NAc), 
4.32-4.17 (m, 3H), 4.00-3.49 (m, 19H), 2.29-2.24 (2s, 3H, NCOCH3 
rotamers), 1.25 (d, 3H, J = 6.6 Hz, MeFuc); 13C NMR (400 MHz, D2O) δ 
176.68, 175.29, 151.12, 150.55, 142.86, 142.18, 110.69, 108.56, 108.23, 
100.20, 100.11, 98.70, 93.08, 86.94, 82.56, 77.43, 77.38, 76.30, 75.49, 
75.33, 75.20, 75.01, 72.47, 72.39, 71.70, 71.18, 70.28, 70.00, 69.62, 69.52, 
69.28, 68.07, 67.70, 66.87, 63.58, 61.28, 61.22, 60.14, 60.00, 40.89, 37.54, 
21.84, 21.26, 15.19, 15.13; ESI-HRMS: m/z calcd for C31H49NO21  [M+Na]+ 
794.2694, found 794.2692. 
Synthesis of oligosaccharide-modified Sepharose particles 
Maleimide-activated Sepharose 4B: NHS-activated Sepharose 4B 
particles (10 mL of commercially available GE Healthcare, 50% vol. slurry 
in isopropanol, 0.110 mmol NHS-ester) were pipetted in a Biorad Poly-
Prep® column and washed four times at 4°C with 0.01M HCl (10mL). The 
particles were then rinsed at 4°C with 0.1M AcONa buffered solution pH 
8.5 (5 mL) then N-(2-aminoethyl)maleimide hydrochloride[26] (0.55 mmol, 
5 equiv.) were added in 5 mL of the same acetate buffer. After 4h in a 
rotary stirrer the particles were washed with water (10 mL) then briefly with 
0.1M NaOH (5 mL) at 4°C to hydrolyze any unreacted NHS ester. The 
resin was then soaked in water with 0.1% sodium azide and stored at 4°C. 
IR (cm-1): 3448 (str,broad), 2938 (med), 1816 (wk, sharp), 1710 (str, sharp), 
1636 (med, amide), 1560 (sml, sharp), 1380 (med, sharp), 1078 (str, med), 
928 (med, sharp).  
The coupling reaction reached 85% conversion as determined by the 
quantification of the remaining carboxylic acid groups on the maleimide-
activated particles as compared to those of hydrolyzed NHS-Sepharose 
4B. Briefly, 1 mL of particles is transferred to a titration vessel and the 
solution is made acidic by addition of 0.01M HCl (5mL) and stirred for an 
hour. The solution is then titrated with 0.01M NaOH and the volume is 
plotted against the conductometry of the solution. The result obtained with 
maleimide-activated Sepharose 4B particles was compared against 
hydrolyzed NHS-Sepharose 4B as indicator of the total acid content.  
Oligosaccharide-modified Sepharose 4B: Maleimide-activated 
Sepharose 4B resin (2 mL, 50% vol. slurry in water, 0.025 mmol) was 
pipetted in a Biorad Poly-Prep® column and be rinsed four times with 1mL 
water. Furyl-modified oligosaccharide (1.25 mmol, 5 equiv.) was then 
added in 1mL water. After 16h in a rotary stirrer at 40°C the particles are 
rinsed with 10 mL of water. The resin is then stored in water with 0.1% 
sodium azide. 
The ligation efficiency reached 85% conversion. The yield was determined 
by quantification of glucose released from the maltose-modified 
Sepharose particles after enzymatic treatment with a glucoamylase. Briefly, 
maltose-modified Sepharose particles (0.2 mL, 50% vol slurry in water) 
were placed in a Biorad Poly-Prep® column, rinsed 4 times with 0.1 M 
acetate buffer (pH 5) and incubated with a large excess of Glucoamylase 
AMGII (500µL of a 1 mg.mL-1 solution in the same buffer). The column was 
stirred 12h at 37°C. The amount of glucose in the supernatant was 
determined by the BCA reducing sugar assay. 
Protein binding and purification  
Enzyme Linked Lectin Assay (ELLA) with Concanavalin A lectin on 
maltose-modified Sepharose particles: Carbohydrate-modified 
particles (0.2 ml, 50%vol slurry in water) were placed in Biorad Poly-Prep® 
column tubes and rinsed with TBS buffer (TRIS 10mM, pH 7.6, 15 mM 
NaCl, 1 mM Ca2+, 1 mM Mg2+) containing 3wt% bovine serum albumin 
(BSA). The particles were let to soak in 500µL of that same buffer for 10 
min to block any non-specific binding site. Particles were then washed with 
TBS containing 0.3% BSA. The particles are then soaked in 0.5mL of fresh 
buffer containing a known amount of HRP conjugated lectin and incubated 
1h at 37°C. The particles were thoroughly washed with TBS buffer and 
then transferred to 0.4 mL of deionized water prior to add 200 µL of OPD-
sigmafast™ solution. After 10 min the overhead solution is transferred to 
1 mL cuvettes and the absorbance was measured at 450 nM. 
Concanavalin A purification on maltose-modified Sepharose 
particles: Maltose-modified particles (1 ml, 50% vol. slurry in water) were 
placed in Biorad Poly-Prep® column tubes and rinsed with PBS buffer (10 
mM, pH 6.8, 15 mM NaCl, 1mM Ca2+, 1mM Mg2+). The particles are then 
soaked in 2 mL of fresh buffer containing 1 mg of Concanavalin A and 3 
mg of bovine serum albumin and then incubated 1h at 37°C. The particles 
were rinsed with PBS and 1 mL fractions were collected for 50 column 
volumes. The buffer was then swapped for a 0.2 M maltose solution in PBS 
and the fractions collected. Each fraction was then titrated for protein 
content using the Bradford assay. Two fractions of each peak were then 
analyzed by electrophoresis on SDS-PAGE. 
Ulex Europaeus lectin purification on H antigen-modified Sepharose 
particles: Blood group H antigen-modified Sepharose particles (1 ml,  
50% vol. slurry in water) were placed in Biorad Poly-Prep® column tubes 
and rinsed with TRIS buffer (10 mM, pH 7.6, 15 mM NaCl). The particles 
are then soaked in 2 mL of fresh buffer containing 100 µg of CF488A™ 
fluorescent-tagged Ulex Europaeus lectin and incubated 1h at 37°C. The 
particles were rinsed with TBS and 1mL fractions were collected for 20 
column volumes. The buffer was then swapped for a 0.2 M solution of 2’-
fucosyl-lactose in TBS and the fractions collected. The fluorescence of 
each fraction was measured at 515 nm with excitation at 488 nm. The 
same protocol was applied to maltose modified particles for a control 
experiment. 
    
 
 
 
 
 
Adsorption of anti-blood group A and B antibodies on blood goup A 
antigen-modified Sepharose particles and blood goup B antigen-
modified Sepharose particles respectively: Monoclonal anti-blood 
group A and B antibodies produced in mouse were fluorescent-tagged 
using Mix-n-Stain™ CF™ 488A antibody labeling kit and Mix-n-Stain™ 
CF™ 568 antibody labeling kit respectively. Blood group A antigen-
modified Sepharose particles (0.2 ml, 50% vol. slurry in water) were placed 
in Biorad Poly-Prep® column tubes and rinsed with TRIS buffer (50 mM, 
pH 7.8, 150 mM NaCl) at 4°C. The particles are then soaked in 200µL of 
fresh buffer containing 50 µL of CF488A™ fluorescent-tagged anti-blood 
group A antibodies and incubated 1h at 4°C. The particles were rinsed with 
5 mL TBS then the particles were pipetted onto a glass slide and observed 
on an epifluorescence microscope. The same protocol was applied to 
Blood group B antigen-modified Sepharose particles. Maltose-modified 
Sepharose particles were treated with the same protocol as a control 
experiment. 
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